These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23920125)

  • 1. Down-regulation and aberrant cytoplasmic expression of GLTSCR2 in prostatic adenocarcinomas.
    Kim JY; Cho YE; Kim GY; Lee HL; Lee S; Park JH
    Cancer Lett; 2013 Oct; 340(1):134-40. PubMed ID: 23920125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of GLTSCR2 expression is correlated with breast cancer progression.
    Moon A; Lim SJ; Jo YH; Lee S; Kim JY; Lee J; Park JH
    Pathol Res Pract; 2013 Nov; 209(11):700-4. PubMed ID: 24054033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses.
    Lee S; Kim JY; Kim YJ; Seok KO; Kim JH; Chang YJ; Kang HY; Park JH
    Cell Death Differ; 2012 Oct; 19(10):1613-22. PubMed ID: 22522597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of GLTSCR2 expression in renal cell carcinomas.
    Cho YE; Lee HL; Lim SJ; Kim YW; Choe BK; Lee S; Park JH
    Pathol Res Pract; 2016 Feb; 212(2):120-4. PubMed ID: 26724143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLTSCR2 contributes to the death resistance and invasiveness of hypoxia-selected cancer cells.
    Kim JY; Park JH; Lee S
    FEBS Lett; 2012 Sep; 586(19):3435-40. PubMed ID: 22850112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas.
    Kim YJ; Cho YE; Kim YW; Kim JY; Lee S; Park JH
    J Pathol; 2008 Oct; 216(2):218-24. PubMed ID: 18729076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of GLTSCR2, a candidate tumor suppressor, is reduced in seborrheic keratosis compared to normal skin.
    Kim JY; Kim HS; Lee S; Park JH
    Pathol Res Pract; 2010 May; 206(5):295-9. PubMed ID: 20185249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Nucleolar Protein GLTSCR2 Is an Upstream Negative Regulator of the Oncogenic Nucleophosmin-MYC Axis.
    Kim JY; Cho YE; Park JH
    Am J Pathol; 2015 Jul; 185(7):2061-8. PubMed ID: 25956029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of GLTSCR2 in the regulation of telomerase activity and chromosome stability.
    Kim JY; An YM; Park JH
    Mol Med Rep; 2016 Aug; 14(2):1697-703. PubMed ID: 27357325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of GLTSCR2 in the DNA Damage Response.
    Kim JY; Seok KO; Kim YJ; Bae WK; Lee S; Park JH
    Am J Pathol; 2011 Sep; 179(3):1257-64. PubMed ID: 21741933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer.
    Kim JY; Cho YE; An YM; Kim SH; Lee YG; Park JH; Lee S
    J Cell Mol Med; 2015 Jun; 19(6):1245-52. PubMed ID: 25818168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene.
    Gao L; Wu GJ; Liu XW; Zhang R; Yu L; Zhang G; Liu F; Yu CG; Yuan JL; Wang H; Yao LB
    Cancer Lett; 2011 Nov; 310(1):94-100. PubMed ID: 21741166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLTSCR2 promotes the nucleoplasmic translocation and subsequent degradation of nucleolar ARF.
    Lee S; Cho YE; Kim SH; Kim YJ; Park JH
    Oncotarget; 2017 Mar; 8(10):16293-16302. PubMed ID: 27323397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [LASS2/TMSG1 gene silencing promotes the invasiveness and metastatic of human prostatic carcinoma cells through increase in vacuolar ATPase activity].
    Xu X; You J; Pei F
    Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):177-83. PubMed ID: 24842017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological aggressiveness evaluation in prostate carcinomas:immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcinomas.
    Cappello F; Palma A; Martorana A; Rappa F; Cabibi D; Barresi E; Melloni D; Farina F; Aragona F
    Eur J Histochem; 2003; 47(2):129-32. PubMed ID: 12777208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
    Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
    Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Jun N-terminal kinase regulates the nucleoplasmic translocation and stability of nucleolar GLTSCR2 protein.
    Lee S; Cho YE; Kim YJ; Park JH
    Biochem Biophys Res Commun; 2016 Mar; 472(1):95-100. PubMed ID: 26903295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo.
    Chen E; Yang F; He H; Lei L; Liu R; Du L; Dong J; Wang M; Yang J
    Oncotarget; 2016 Apr; 7(15):19813-23. PubMed ID: 27009808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The down-regulated ING5 expression in lung cancer: a potential target of gene therapy.
    Zhao S; Yang XF; Shen DF; Gao Y; Shi S; Wu JC; Liu HX; Sun HZ; Su RJ; Zheng HC
    Oncotarget; 2016 Aug; 7(34):54596-54615. PubMed ID: 27409347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.